Nathan Weinstein
Stock Analyst at Aegis Capital
(0.28)
# 4,044
Out of 4,829 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.13 | +6,979.65% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.76 | +1,873.68% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.49 | +1,112.61% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.99 | +3,447.18% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.07 | +189.86% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.24 | +1,239.29% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $6.70 | +49.25% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $18.65 | +162.73% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.36 | +10,970.11% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.98 | +54,171.36% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.23 | +2,339.02% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.56 | +1,685.71% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $19.43 | +723.47% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $24.79 | +125.90% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $1.44 | +1,775.00% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.97 | +3,514.58% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.15 | +458.14% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $9.58 | +682.88% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $3.55 | +2,378.87% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.32 | +7,658.62% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $9 | $0.43 | +1,992.05% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.24 | +167.18% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $10.42 | +2,011.32% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $2.66 | +219.55% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.13
Upside: +6,979.65%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.76
Upside: +1,873.68%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.49
Upside: +1,112.61%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.99
Upside: +3,447.18%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.07
Upside: +189.86%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.24
Upside: +1,239.29%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $6.70
Upside: +49.25%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $18.65
Upside: +162.73%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.36
Upside: +10,970.11%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.98
Upside: +54,171.36%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.23
Upside: +2,339.02%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.56
Upside: +1,685.71%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $19.43
Upside: +723.47%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $24.79
Upside: +125.90%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $1.44
Upside: +1,775.00%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.97
Upside: +3,514.58%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.15
Upside: +458.14%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $9.58
Upside: +682.88%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $3.55
Upside: +2,378.87%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.32
Upside: +7,658.62%
Aug 3, 2020
Maintains: Buy
Price Target: $13 → $9
Current: $0.43
Upside: +1,992.05%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.24
Upside: +167.18%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $10.42
Upside: +2,011.32%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $2.66
Upside: +219.55%